Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

A Phase II Study of Oxaliplatin in Association With 5FU and Folinic Acid in the Treatment of Subjects With Non-Surgical or Advanced Metastatic Gastric Cancer

Phase 2

Completed

Conditions: Stomach Neoplasms

First Posted Date: 2008-02-11

Last Posted Date: 2008-03-25

Lead Sponsor: Sanofi

Target Recruit Count: 21

Registration Number: NCT00611507

Locations: 🇨🇴
Sanofi-Aventis, Bogota, Colombia

The Incidence of Hypoglycemia in Insulin Glargine-Treated Subjects With Diabetes Mellitus Upon Switching Between Bedtime and Morning Dosing

Phase 4

Completed

Conditions: Diabetes Mellitus

First Posted Date: 2008-02-07

Last Posted Date: 2008-03-28

Lead Sponsor: Sanofi

Target Recruit Count: 22

Registration Number: NCT00609895

Locations: 🇲🇽
Sanofi-Aventis, Monterrey, Mexico

Rasburicase (Fasturtec) Registration Trial

Phase 3

Terminated

Conditions: Hyperuricemia

Interventions: Drug: Allopurinol
Drug: Rasburicase

First Posted Date: 2008-02-05

Last Posted Date: 2014-05-08

Lead Sponsor: Sanofi

Target Recruit Count: 10

Registration Number: NCT00607152

Locations: 🇨🇳
Sanofi-Aventis Administrative Office, Shanghai, China

Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Insulin glulisine
Drug: Insulin lispro
Drug: Insulin aspart

First Posted Date: 2008-02-05

Last Posted Date: 2010-08-31

Lead Sponsor: Sanofi

Target Recruit Count: 289

Registration Number: NCT00607087

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom

Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens

Phase 3

Terminated

Conditions: Colorectal Neoplasms

Interventions: Drug: Placebo
Drug: Xaliproden

First Posted Date: 2008-01-29

Last Posted Date: 2016-05-05

Lead Sponsor: Sanofi

Target Recruit Count: 102

Registration Number: NCT00603577

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom

S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen

Phase 3

Terminated

Conditions: Pancreatic Neoplasm
Neoplasm Metastasis

Interventions: Drug: 5-Fluorouracil
Drug: S-1

First Posted Date: 2008-01-28

Last Posted Date: 2016-05-26

Lead Sponsor: Sanofi

Target Recruit Count: 61

Registration Number: NCT00602745

Locations: 🇹🇳
Sanofi-Aventis Administrative Office, Megrine, Tunisia

Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease

Phase 2

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: SSR180711C
Drug: placebo
Drug: donepezil

First Posted Date: 2008-01-28

Last Posted Date: 2009-07-20

Lead Sponsor: Sanofi

Target Recruit Count: 1

Registration Number: NCT00602680

Locations: 🇫🇷
Sanofi-Aventis Administrative Office, Paris, France

PulmonarOM (Bacterial Lysates) in Respiratory Tract Infections

Phase 4

Completed

Conditions: Respiratory Tract Infections

Interventions: Drug: Bacterial Lysates
Drug: placebo

First Posted Date: 2008-01-23

Last Posted Date: 2009-09-21

Lead Sponsor: Sanofi

Target Recruit Count: 80

Registration Number: NCT00599417

Locations: 🇲🇽
Sanofi-Aventis Administrative Office, Col. Coyoacan, Mexico

Leflunomide EfficAcy Response Related to Dosing Regimen in Early Rheumatoid Arthritis

Phase 3

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: leflunomide

First Posted Date: 2008-01-16

Last Posted Date: 2010-10-13

Lead Sponsor: Sanofi

Target Recruit Count: 124

Registration Number: NCT00596206

Locations: 🇷🇴
Sanofi-Aventis Administrative Office, Bucuresti, Romania

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

Phase 3

Terminated

Conditions: Atrial Fibrillation

Interventions: Drug: Idrabiotaparinux sodium
Drug: Warfarin
Drug: Placebo (for warfarin)
Drug: Placebo (for idrabiotaparinux)
Drug: Placebo (for avidin)
Drug: Avidin

First Posted Date: 2007-12-24

Last Posted Date: 2016-03-21

Lead Sponsor: Sanofi

Target Recruit Count: 3773

Registration Number: NCT00580216

Locations: 🇺🇸
Sanofi-Aventis Investigational Site Number 840128, Philadelphia, Pennsylvania, United States
🇺🇸
Sanofi-Aventis Investigational Site Number 840181, Pittsburgh, Pennsylvania, United States
🇺🇸
Sanofi-Aventis Investigational Site Number 840146, Cleveland, Ohio, United States

and more 535 locations

Home Terms & Conditions Privacy Policy